Every one of those 1 sits in a single category, funding. Of the tracked stories, 1 of 1 also mention Anthony Fauci, the most common co-covered peer. We currently track 1 Biotech story that mention Wuhan Institute of Virology, all published on July 31, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Wuhan Institute of Virology
Every one of those 1 sits in a single category, funding. Of the tracked stories, 1 of 1 also mention Anthony Fauci, the most common co-covered peer. We currently track 1 Biotech story that mention Wuhan Institute of Virology, all published on July 31, 2026. Each carries 2 original sources on average.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Wuhan Institute of Virology. Shared-story counts are live from our verified record — not editorial picks.
Sens. Rand Paul and Ron Johnson publicly call for legal challenges to the pardon, state-level prosecution, and full investigations into Fauci’s actions.
Gabbard releases intelligence files
Outgoing DNI Tulsi Gabbard declassifies and releases trove of documents alleging Fauci’s deception and funding of Wuhan gain-of-function research.
Preemptive pardon granted
President Biden issues a preemptive pardon to Fauci before leaving office, covering potential federal crimes related to the pandemic.
Fauci testifies to Congress
Fauci testifies that he had no contact with intelligence agencies regarding viral research, a claim now contradicted by Gabbard's files.
Outgoing DNI Tulsi Gabbard’s intelligence release alleges Dr. Anthony Fauci directed millions in taxpayer dollars to fund dangerous bat coronavirus research at the Wuhan lab, threatening public trust and likely triggering a regulatory crackdown on gain-of-function studies across the biotech sector.